Showing 91-100 of 725 results for "".
Can Vitamin B3 Reduce Recurrence of NMSC?
https://practicaldermatology.com/topics/practice-management/can-vitamin-b3-reduce-recurrence-of-nmsc/21165/A common OTC vitamin supplement shows early promise in preventing secondary NMSCs. Is it time to recommend it?Therapeutics Focus: Corticosteroids
https://practicaldermatology.com/topics/psoriasis/therapeutics-focus-corticosteroids/21432/New products and pharmacologic developmentsUpdate on the Treatment of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/update-on-the-treatment-of-actinic-keratoses/21630/From mainstay therapies to newly approved agents, treatment options for actinic keratoses are growing.Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults
https://practicaldermatology.com/topics/general-topics/pain-free-dermatology-minimizing-discomfort-in-procedures-for-children-and-adults/21000/It may be useful to review some of the techniques and approaches used to minimize pain.Research Update
https://practicaldermatology.com/topics/skin-cancer-photoprotection/research-update/22942/Preventive Strategies: Cutting Costs, Exploring SafetyDermWireTV: AAD VMX Highlights, Upneeq Launches for Ptosis
https://practicaldermatology.com/topics/practice-management/dermwiretv-aad-vmx-highlights-upneeq-launches-for-ptosis/19931/The American Academy of Dermatology's VMX format delivers updates on a range of hot topics in dermatology, including an update on the COVID-19 dermatology vaccine registry from Esther Freeman, MD and teledermatology from Jules Lipoff, MD. Upneeq, a newly launched oxymetazoline eyedrop from RVL pharmDupilumab For the Management of Pembrolizumab-induced Rash: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/dupilumab-for-the-management-of-pembrolizumab-induced-rash-a-case-report/23841/Is Irritable Bowel Linked to Irritable Skin?
https://practicaldermatology.com/columns/clinical-focus-1/is-irritable-bowel-linked-to-irritable-skin/23324/Exploring irritable bowel syndrome’s link to dermatologic conditions.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivPregnancy and Melanoma: What We Know About the Risks
https://practicaldermatology.com/topics/practice-management/pregnancy-and-melanoma-what-we-know-about-the-risks/21041/Against a backdrop of conflicting findings, a new study suggests a significant risk associated with melanoma during pregnancy.